Janssen Research & Development, LLC: clinical-trial pipeline
Janssen Research & Development, LLC is the sponsor of 1,214 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 178 are not yet finished and 5 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials178
Phase 2/3 and 3307
Countries89
New in 90 days5
Trials by phase
| Phase | Trials |
|---|---|
| Phase 1 | 496 |
| Phase 3 | 293 |
| Phase 2 | 234 |
| Not applicable | 91 |
| Phase 1/2 | 39 |
| Phase 4 | 34 |
| Phase 2/3 | 14 |
| Early phase 1 | 13 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 903 |
| Terminated | 99 |
| Active, not recruiting | 97 |
| Recruiting | 75 |
| Withdrawn or not authorised | 32 |
| Not yet recruiting | 6 |
| Suspended or halted | 2 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 296 |
| Immunology and rheumatology | 185 |
| Psychiatry and mental health | 111 |
| Gastroenterology and liver | 107 |
| Infectious disease and vaccines | 102 |
| Nephrology and urology | 86 |
| Dermatology | 79 |
| Neurology | 45 |
| Metabolic and endocrine (diabetes, obesity) | 43 |
| Respiratory | 42 |
| Cardiovascular | 36 |
| Rare and genetic diseases | 27 |
Countries
| Country | Trials |
|---|---|
| United States | 681 |
| Belgium | 375 |
| Spain | 350 |
| Germany | 326 |
| Poland | 284 |
| France | 281 |
| Japan | 264 |
| United Kingdom | 261 |
| Canada | 230 |
| Netherlands | 196 |
| South Korea | 194 |
| Australia | 184 |
| Brazil | 165 |
| Russia | 154 |
| Taiwan | 152 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-15 | New trial posted | A Phase 3, Multicenter, Open Label, Basket, Long-term Extension Study of Icotrokinra in P… |
| 2026-09-23 | New trial posted | A research trial in healthy participants to learn how a new formulation of JNJ‑77730614 i… |
| 2026-09-21 | New trial posted | A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer |
| 2026-09-16 | New trial posted | A Study of Long Term Persistency of Guselkumab in Adult Participants With Inflammatory Bo… |
| 2026-09-16 | New trial posted | A Phase 3 Randomized Study Comparing Ramantamig Plus Daratumumab Versus Investigator’s Ch… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT06220604 | A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-AD… | Phase 3 | Active, not recruiting | Australia, Brazil, Canada, Germany +8 |
| NCT06178614 | A Study of JNJ-87890387 for Advanced Solid Tumors | Phase 1 | Recruiting | Spain, France, United States |
| NCT06120140 | Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated… | Phase 2 | Active, not recruiting | Argentina, Brazil, China, Germany +6 |
| NCT05453903 | A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies | Phase 1 | Active, not recruiting | Australia, Canada, Germany, Spain +4 |
| NCT05316155 | Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer | Phase 1/2 | Active, not recruiting | Canada, Germany, Spain, Israel +4 |
| NCT04181827 | A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pom… | Phase 3 | Active, not recruiting | Australia, Belgium, Germany, Denmark +12 |
| NCT03473743 | A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer | Phase 1/2 | Active, not recruiting | Belgium, Brazil, Belarus, Spain +8 |
| NCT05714202 | A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guér… | Phase 3 | Active, not recruiting | Argentina, Australia, Belgium, Brazil +17 |
| NCT04497844 | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Pr… | Phase 3 | Active, not recruiting | Argentina, Australia, Belgium, Bulgaria +28 |
| NCT03748641 | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Pr… | Phase 3 | Active, not recruiting | Argentina, Australia, Belgium, Bulgaria +24 |
| NCT04923893 | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed A… | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Belgium +22 |
| NCT03390504 | A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced U… | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Belgium +22 |
| NCT05498428 | A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Fa… | Phase 2 | Recruiting | Brazil, China, Germany, Spain +8 |
| NCT05338775 | A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inh… | Phase 1 | Active, not recruiting | Germany, Spain, France, United States |
| NCT05488314 | A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Canc… | Phase 1/2 | Active, not recruiting | Brazil, Canada, China, Germany +8 |
| NCT05421663 | A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma | Phase 1/2 | Not yet recruiting | Australia, Canada, Germany, Denmark +7 |
| NCT04929210 | A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis A… | Phase 4 | Active, not recruiting | Argentina, Australia, Bulgaria, Canada +21 |
| NCT04577833 | A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer | Phase 1 | Active, not recruiting | Belgium, Spain, France, United Kingdom +7 |
| 2023-509435-11-00 | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Amivantamab (JNJ61186372), a Human Bispecific… | Phase 1 | Active, not recruiting | France, Italy |
| NCT06211764 | A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invas… | Phase 3 | Active, not recruiting | Argentina, Belgium, Brazil, China +10 |
| NCT05327114 | Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (C… | Phase 2/3 | Active, not recruiting | Argentina, Australia, Canada, China +15 |
| NCT05050097 | A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma | Phase 1 | Active, not recruiting | Australia, Belgium, France, United Kingdom +2 |
| NCT04640623 | A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With No… | Phase 2 | Active, not recruiting | Australia, Belgium, Canada, Germany +12 |
| NCT05242484 | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Acti… | Phase 2 | Active, not recruiting | Argentina, Austria, Australia, Belgium +33 |
| NCT05242471 | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Acti… | Phase 2 | Active, not recruiting | Austria, Australia, Belgium, Bulgaria +32 |
Website: janssen.com. All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Janssen Research & Development, LLC clinical trials: 178 open, 307 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/janssen-com/, data as of 2026-10-25.